Mitazalimab

DRUG3 trials

Sponsors

Joachim Aerts, MD PhD, University of Pennsylvania, UNICANCER

Conditions

Biliary Tract Cancer (BTC)Metastatic Pancreatic CancerPancreatic Ductal Adenocarcinoma

Phase 1

MesoPher/Mitazalimab-combination Therapy in Metastatic Pancreatic Disease (REACtiVe-2 Trial)

CompletedNCT05650918

Joachim Aerts, MD PhDMetastatic Pancreatic Cancer

Start: 2021-08-30End: 2023-05-23Updated: 2023-10-12

Phase 2

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

RecruitingNCT07199764

University of PennsylvaniaPancreatic Ductal Adenocarcinoma

Start: 2025-11-25End: 2028-12-01Target: 100Updated: 2026-03-06

Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

Not yet recruitingNCT07437287

UNICANCERBiliary Tract Cancer (BTC)

Start: 2026-07-01End: 2031-10-01Target: 160Updated: 2026-02-27

Related Papers

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

2025-11-281 citations